Waist Circumference and BMI in Relation to Serum High Sensitivity C-Reactive Protein (hs-CRP) in Cuban Americans With and Without Type 2 Diabetes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Procedure
2.3. Statistical Analysis
3. Results
4. Discussion
Acknowledgments
References and Notes
- American Diabetes Association. Total prevalence of diabetes and pre-diabetes.
- Center for Disease Control. CDC Diabetes Fact Sheet 2007.
- Schulze, MB; Rimm, EB; Li, T; Rifai, N; Stampfer, MJ; Frank, B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004, 27, 889–893. [Google Scholar]
- Howard, BV; Rodriguez, BL; Bennett, PH; Harris, MI; Hammam, R; Kuller, LH; Pearson, TA; Wylie-Rosett, J. Prevention Conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002, 105, 132–137. [Google Scholar]
- Rijelijkhutzen, JM; Nijpels, G; Heine, RJ; Bouter, LM; Stehouwer, CDA; Dekker, JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes. Diabetes Care 2007, 30, 332–336. [Google Scholar]
- Hummer, RA; Rogers, RG; Amir, SH; Forbes, D; Frisbie, WP. Adult mortality differentials among Hispanic subgroups and non-Hispanic whites. Soc. Sci. Q 2000, 81, 459–476. [Google Scholar]
- Flegal, KM; Ezzati, TM; Harris, MI; Haynes, SG; Juarez, RZ; Knowler, WC; Perez-Stable, EJ; Stern, MP. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Examination Survey, 1982–1984. Diabetes Care 1991, 14, 628–638. [Google Scholar]
- Ridker, PM; Hennekens, CH; Buring, JE; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med 2000, 342, 836–843. [Google Scholar]
- Danesh, J; Whincup, P; Walker, M; Lennon, L; Thomson, A; Appleby, P; Gallimore, RJ; Pepys, MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321, 199–204. [Google Scholar]
- Soinio, M; Marniemi, M; Laasko, S; Lehto, J; Ronnemaa, T. High sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7 year follow up study. Diabetes Care 2006, 29, 329–333. [Google Scholar]
- Bullo, M; Garcia-Lorda, P; Megias, I; Salas-Salvado, J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res 2003, 85, 3338–3342. [Google Scholar]
- Yudkin, JS; Stehouwer, CDA; Emeis, JJ; Coppack, SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Int. J. Obes 1999, 19, 972–978. [Google Scholar]
- Santos, AC; Lopes, C; Guimaraes, JT; Barros, H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int. J. Obes 2005, 29, 1452–1456. [Google Scholar]
- Shemesh, T; Rowley, KG; Jenkins, A; Brimblecombe, J; Best, JD; O’Dea, K. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. Int. J. Obes 2007, 31, 103–108. [Google Scholar]
- Onat, A; Can, G; Hergenc, G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metab. Clin. Experim 2008, 57, 207–214. [Google Scholar]
- Farah, R; Shurtz-Swirski, R; Lapin, O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc. Diabetol 2008, 22, 7–20. [Google Scholar]
- Stewart, MW; Cirkel, DT; Furuseth, K; Donaldson, J; Biswas, N; Starkie, MG; Phenekos, C; Hamann, A. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet. Med 2006, 23, 1069–1078. [Google Scholar]
- Palmas, W; Ma, S; Psaty, B; Goff, DC; Darwin, C; Barr, RG. Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis. Am. J. Hypertens 2007, 20, 233–241. [Google Scholar]
- O’brien, SM; Scott, LV; Dinan, TG. Antidepressant therapy and C-reactive protein levels. Br. J. Psychiatry 2006, 188, 449–452. [Google Scholar]
- Kennon, S; Price, CP; Mills, PG; Ranjadayalan, K; Cooper, J; Clarke, H; Timmis, AD. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J. Am. Coll. Cardiol 2001, 37, 1266–1270. [Google Scholar]
- Wolter, J; Seeney, S; Bell, S; Bowler, S; Masel, P; McCormack, J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57, 212–216. [Google Scholar]
- Walsh, BW; Paul, S; Wild, RA; Dean, RA; Tracy, RP; Cox, DA; Anderson, PW. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A Randomized, Controlled Trial. J. Clin. Endocrinol. Metab 2000, 85, 214–218. [Google Scholar]
- Dehghan, A; Kardys, I; De Maat, MPM; Uitterlinden, AG; Sijbrands, EJG; Bootsma, AH; Stijnen, T; Hofman, A; Schram, MT; Witteman, JCM. Genetic variation, C-reactive protein levels and incidence of diabetes. Diabetes 2007, 56, 872–878. [Google Scholar]
- Onat, A; Sari, I; Hergenc, G; Yazici, M; Uyarel, H; Can, G; Sansoy, V. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metab. Clin. Experim 2007, 56, 348–356. [Google Scholar]
- Patel, DA; Srinivasan, SR; Xu, JH; Li, S; Chen, W; Berenson, GS. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metab. Clin. Experim 2006, 55, 699–705. [Google Scholar]
- Florez, H; Castillo-Florez, S; Mendez, A; Casanova-Romero, P; Larreal-Urdaneta, C; Lee, D; Goldberg, R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diaetes Res. Clin. Pract 2006, 71, 92–100. [Google Scholar]
- Callaway, CW; Chumlea, WC; Bouchard, C; Himes, JH; Lohman, TG; Martin, AD; Mitchell, CD; Mueller, WH; Roche, AF; Seefeldt, VD. Circumferences; Lohman, TG, Roche, AF, Martorell, R, Eds.; Anthropometric standardization reference manual Human Kinetics: Champaign, IL, USA, 1988; pp. 39–54. [Google Scholar]
- Roberts, WL; Sedrick, R; Moulton, L; Spencer, A; Rifai, N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological; applications. Clin. Chem 2000, 46, 461–468. [Google Scholar]
- Muscari, A; Bastagli, L; Poggiopollini, G; Tomassetti, V; Massarelli, G; Cappelletti, O; Plate, L; Boni, P; Puddu, P. Different associations of C-reactive protein, fibrinogen and C3 with traditional risk factors in middle-aged men. Inter. J. Cardiol 2002, 83, 63–67. [Google Scholar]
- Efstratiadis, G; Tsiaousis, G; Athyros, VS; Karagianni, D; Pavlitou-Tsiontsi, A; Giannakou-Darda, A; Manes, C. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006, 57, 303–310. [Google Scholar]
- Pawson, IG; Martorell, R; Mendoza, FE. Prevalence of overweight and obesity in US Hispanic populations. Am. J. Clin. Nutr 1991, 53, 1522S–1528S. [Google Scholar]
- Denney, JT; Krueger, PM; Rogers, RG; Boardman, JD. Race/ethnic and sex differentials in body mass among US adults. Ethn. Dis 2004, 14, 389–398. [Google Scholar]
- Smith, CA; Barnett, E. Diabetes-related mortality among Mexican Americans, Puerto Ricans, and Cuban Americans in the United States. Rev. Panam. Salud Publica 2005, 18, 381–387. [Google Scholar]
- Haffner, SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol 2006, 96, 3A–11A. [Google Scholar]
- Bartels, DW; Davidson, MH; Gong, WC. Type 2 diabetes and cardiovascular disease: reducing the risk. J. Manag. Care Pharm 2007, 13, S2–S15. [Google Scholar]
- Williams, K; Tchernof, A; Hunt, KJ; Wagenknecht, LE; Haffner, SM; Sniderman, AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008, 57, 3289–3296. [Google Scholar]
- Dandona, T; Chaudhuri, A; Ghanim, H; Mohanty, P. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Amer. Coll. Cardiol 2009, 53, S14–S20. [Google Scholar]
- Huang, CC. Treatment targets for diabetic patients on peritoneal dialysis: any evidence? Perit. Dial. Int 2007, 27, 176–179. [Google Scholar]
Variables | Without Diabetes (n = 178) | With Diabetes (n = 177) | P-value† |
---|---|---|---|
Age (years) | 62.5 ± 11.4 | 65.3 ± 12.1 | 0.023 |
Gender (female %) | 65 | 60 | 0.322 |
BMI (kg/m2) | 30.1 ± 5.2 | 31.6 ± 6.6 | 0.022 |
WC (cm) | 100.3 ± 12.4 | 105.7 ± 14.7 | 0.001 |
Ln hs-CRP (mg/L) | 1.03 ± 1.18 | 1.04 ± 1.23 | 0.901 |
Active smokers (%) | 18 | 15 | 0.667 |
NSAID (yes %) | 50 | 31 | 0.001 |
Cholesterol meds (yes %) | 18 | 21 | 0.510 |
Hypertension meds (yes %) | 47 | 53 | 0.289 |
Depression meds (yes %) | 14 | 11 | 0.516 |
Diabetes meds (yes %) | 0 | 82.5 | 0.001 |
FPG (mg/dl) | 98.0 ± 17.9 | 146.1 ± 65.7 | 0.001 |
HbA1c (%) | 5.9 ± 0.6 | 7.5 ± 1.5 | 0.001 |
Parameter† | B | SE | T | P-value‡ |
---|---|---|---|---|
WC | 0.043 | 0.007 | 6.183 | <0.001 |
Diabetes_Status*WC | −0.017 | 0.009 | −1.850 | 0.065 |
Gender | −0.333 | 0.129 | −2.589 | 0.010 |
Parameter† | B | SE | T | P-value‡ |
---|---|---|---|---|
BMI | ||||
Without Diabetes | 0.099 | 656 | −1.95 | <0.001 |
With Diabetes | 0.055 | 0.013 | 4.09 | <0.001 |
Diabetes_Status *BMI | −0.044 | 0.021 | −2.089 | 0.037 |
Males | |||
Parameter | Without diabetes (n = 60) | With Diabetes (n = 69) | P-value† |
Age (years) | 62.6 ± 11.4 | 63.8 ± 11.3 | 0.551 |
BMI (kg/m2) | 29.4 ± 5.1 | 30.3 ± 5.3 | 0.325 |
WC (cm) | 102.9 ± 13.3 | 106.6 ± 13.7 | 0.123 |
Ln hs-CRP | 0.81 ± 1.18 | 0.95 ± 1.21 | 0.518 |
Females | |||
Parameter | Without diabetes (n = 118) | With Diabetes (n = 108) | P-value† |
Age (years) | 65.6 ± 11.3 | 66.11 ± 12.4 | 0.016 |
BMI (kg/m2) | 30.5 ± 5.2 | 32.4 ± 7.1 | 0.024 |
WC (cm) | 98.9 ± 11.8 | 105.1 ± 15.3 | 0.001 |
Ln hs-CRP | 1.1 ± 1.2 | 1.1 ± 1.3 | 0.838 |
Diabetes Status | Waist Circumference | P-value† | ||
B | SE | t | ||
Without diabetes | 0.048 | 0.011 | 4.41 | <0.001 |
With Diabetes | 0.004 | 0.010 | 0.37 | 0.712 |
BMI | P-value† | |||
B | SE | t | ||
Without diabetes | 0.127 | 0.029 | 4.35 | <0.001 |
With Diabetes | 0.020 | 0.027 | 0.74 | 0.458 |
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Huffman, F.G.; Whisner, S.; Zarini, G.G.; Nath, S. Waist Circumference and BMI in Relation to Serum High Sensitivity C-Reactive Protein (hs-CRP) in Cuban Americans With and Without Type 2 Diabetes. Int. J. Environ. Res. Public Health 2010, 7, 842-852. https://doi.org/10.3390/ijerph7030842
Huffman FG, Whisner S, Zarini GG, Nath S. Waist Circumference and BMI in Relation to Serum High Sensitivity C-Reactive Protein (hs-CRP) in Cuban Americans With and Without Type 2 Diabetes. International Journal of Environmental Research and Public Health. 2010; 7(3):842-852. https://doi.org/10.3390/ijerph7030842
Chicago/Turabian StyleHuffman, Fatma G., Suzanne Whisner, Gustavo G. Zarini, and Subrata Nath. 2010. "Waist Circumference and BMI in Relation to Serum High Sensitivity C-Reactive Protein (hs-CRP) in Cuban Americans With and Without Type 2 Diabetes" International Journal of Environmental Research and Public Health 7, no. 3: 842-852. https://doi.org/10.3390/ijerph7030842